UCI 趙 Chao Family Comprehensive Cancer Center



Laguna Hills

Clinical Research Treatment Trial Flowchart

Open to Accrual | Low Accruing | Pending Activation/Suspended

CLL NEWLY DIAGNOSED: HIGH RISK

SWOG S1925

Venetoclax+Obnutumab early intervention vs. delayed therapy in asymptomatic high-risk CLL/SLL

Mechanism: BCL2 inhibitor +anti-CD20 monoclonal antibody

PI: Coombs
Coord: K. McAbee
Accrual: 5/10

MELANOMA: NON-TREATMENT

UCI 19-135

DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)

PI: Yamamoto
Coord: A. Reipolska
Accrual: 106/130